Jinyu Bio-Technology Co (SHSE:600201) EBIT: ¥105 Mil (TTM As of Mar. 2026)


SHSE:600201 Jinyu Bio-Technology Co Ltd SHSE:600201
68 GF Score
Price ¥11.44
GF Value ¥8.19
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Jinyu Bio-Technology Co EBIT?

Jinyu Bio-Technology Co SHSE:600201 -5.30% 68 EBIT is ¥105 Mil as of Mar. 2026. GuruFocus rates SHSE:600201 with a GF Score™ of 68/100 and a GF Value™ of ¥8.19 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Jinyu Bio-Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥97 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥105 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jinyu Bio-Technology Co's annualized ROC % for the quarter that ended in Mar. 2026 was 6.43%. Jinyu Bio-Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 18.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jinyu Bio-Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.86%.


Jinyu Bio-Technology Co  (SHSE:600201) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jinyu Bio-Technology Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=353.056 * ( 1 - 15.5% )/( (4615.705 + 4669.937)/ 2 )
=298.33232/4642.821
=6.43 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6611.572 - 610.803 - ( 1385.064 - max(0, 720.53 - 2343.742+1385.064))
=4615.705

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6536.935 - 547.293 - ( 1319.705 - max(0, 648.312 - 2375.14+1319.705))
=4669.937

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Jinyu Bio-Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=386.936/( ( (1887.102 + max(182.388, 0)) + (1842.343 + max(356.687, 0)) )/ 2 )
=386.936/( ( 2069.49 + 2199.03 )/ 2 )
=386.936/2134.26
=18.13 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(591.086 + 269.129 + 41.273) - (610.803 + 0 + 108.297)
=182.388

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(695.714 + 259.584 + 48.648) - (547.293 + 0 + 99.966)
=356.687

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jinyu Bio-Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=105.414/12214.144
=0.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jinyu Bio-Technology Co EBIT Related Terms


Jinyu Bio-Technology Co EBIT Historical Data

* Premium members only.

The historical data trend for Jinyu Bio-Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jinyu Bio-Technology Co EBIT Chart

Jinyu Bio-Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 413.32 250.40 315.88 130.41 105.09

Jinyu Bio-Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.41 -21.38 104.51 -74.45 96.73

SHSE:600201 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Jinyu Bio-Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jinyu Bio-Technology Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jinyu Bio-Technology Co's EV-to-EBIT falls into.


SHSE:600201
68GF Score
Jinyu Bio-Technology Co Ltd SHSE:600201
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jinyu Bio-Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥105 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥105 Mil mean?
Jinyu Bio-Technology Co (SHSE:600201) has a EBIT of ¥105 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Jinyu Bio-Technology Co.
Is Jinyu Bio-Technology Co's EBIT too high?
Jinyu Bio-Technology Co's current EBIT is ¥105 Mil. Overall, Jinyu Bio-Technology Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinyu Bio-Technology Co's EBIT compare to VRTX and REGN?
Jinyu Bio-Technology Co's EBIT of ¥105 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Jinyu Bio-Technology Co. Jinyu Bio-Technology Co's current EBIT is ¥105 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinyu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.19, compared to a current price of ¥11.44 — trading 39.7% above its estimated fair value. The current EBIT is ¥105 Mil. Jinyu Bio-Technology Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current EBIT is ¥105 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?

Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued. The current stock price of ¥11.44 is trading 39.7% above its estimated GF Value™ of ¥8.19. GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.

Key valuation signals for SHSE:600201:

  • EBIT: ¥105 Mil
  • GF Value™: ¥8.19 vs. price of ¥11.44 (39.7% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jinyu Bio-Technology Co Business Description

Address No.1, Jinyu Street, Shaeryu Industrial Park, Economic and Technological Development Zone, Inner Mongolia Autonomous Region, Hohhot, CHN, 010030
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
68GF Score

Get the complete analysis for SHSE:600201

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.44
Price
¥8.19
GF Value